Source item
Open original source ↗Wow! @C_Angermayer is selling his psychedelic biotech company $ATAI for ~$3.8 billion to the largest biotech company in the world, Lilly.
Not only a well-deserved return for ATAI shareholders, this transaction validates Christian’s heartfelt mission and vision.
@C_Angermayer’s work with $ATAI has been one of the biggest catalysts of the psychedelic renaissance. Now clinical trials are validating how important psychedelics will be to TRD (treatment resistant depression) and potentially PTSD and broad-based mental health.
Long before psychedelics were accepted, fashionable, or investable, @C_Angermayer’s life’s mission was to reactivate them and bring back hope and health for those who had lost both. You did it, Christian. Congratulations! Thank you, and may God continue to bless you!🙏
3 segments
Segment 1 · characters 0–262 · Original segment ↗
Segment 2 · characters 264–527 · Original segment ↗
Segment 3 · characters 529–798 · Original segment ↗
Quoted context
These are the quoted author’s words.
Letting go is never easy. Over the past few weeks, I've found myself getting a little starry-eyed thinking about $ATAI But ten years ago, psychedelics needed an evangelist. Today, they need commercialization. In my latest blog post, I share my thoughts on the future of medical psychedelics, my investment philosophy, and why I believe psychedelics could become an essential tool for humanity as we enter what I expect will be the most disruptive, most exciting, and most challenging period in our history.
C_Angermayer ↗